Ascendent Capital Partners II, L.P. - Net Worth and Insider Trading

Ascendent Capital Partners II, L.P. Net Worth

The estimated net worth of Ascendent Capital Partners II, L.P. is at least $604 Million dollars as of 2024-09-28. Ascendent Capital Partners II, L.P. is the 2201 Interest of corporation controlled by you of SciClone Pharmaceuticals (Holdings) Ltd and owns about 32,259,037 shares of SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) stock worth over $604 Million. Details can be seen in Ascendent Capital Partners II, L.P.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ascendent Capital Partners II, L.P. has not made any transactions after 2023-12-07 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Ascendent Capital Partners II, L.P.

Ascendent Capital Partners II, L.P. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ascendent Capital Partners II, L.P. owns 1 companies in total, including SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) .

Click here to see the complete history of Ascendent Capital Partners II, L.P.’s form 4 insider trades.

Insider Ownership Summary of Ascendent Capital Partners II, L.P.

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:06600	SciClone Pharmaceuticals (Holdings) Ltd	2023-12-07	2201 Interest of corporation controlled by you

Ascendent Capital Partners II, L.P. Latest Holdings Summary

Ascendent Capital Partners II, L.P. currently owns a total of 1 stock. Ascendent Capital Partners II, L.P. owns 32,259,037 shares of SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) as of December 7, 2023, with a value of $604 Million.

Latest Holdings of Ascendent Capital Partners II, L.P.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:06600	SciClone Pharmaceuticals (Holdings) Ltd	2023-12-07	32,259,037	18.72	603,889,173

Holding Weightings of Ascendent Capital Partners II, L.P.

Ascendent Capital Partners II, L.P. Form 4 Trading Tracker

According to the SEC Form 4 filings, Ascendent Capital Partners II, L.P. has made a total of 4 transactions in SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in SciClone Pharmaceuticals (Holdings) Ltd is the sale of 29,600,000 shares on December 7, 2023, which brought Ascendent Capital Partners II, L.P. around $0.

Insider Trading History of Ascendent Capital Partners II, L.P.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ascendent Capital Partners II, L.P. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Ascendent Capital Partners II, L.P. Ownership Network

Ownership Network List of Ascendent Capital Partners II, L.P.

No Data

Ownership Network Relation of Ascendent Capital Partners II, L.P.

Ascendent Capital Partners II, L.P. Owned Company Details

What does SciClone Pharmaceuticals (Holdings) Ltd do?

Who are the key executives at SciClone Pharmaceuticals (Holdings) Ltd?

Ascendent Capital Partners II, L.P. is the 2201 Interest of corporation controlled by you of SciClone Pharmaceuticals (Holdings) Ltd. Other key executives at SciClone Pharmaceuticals (Holdings) Ltd include 2201 Interest of corporation controlled by you UBS Group AG , 2101 Beneficial owner Zhao Hong , and Gl Capital Management Gp Limited .

SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) Insider Trades Summary

Over the past 18 months, Ascendent Capital Partners II, L.P. made 2 insider transaction in SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) with a net sale of 0. Other recent insider transactions involving SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) include a net purchase of 354,500 shares made by UBS Group AG , a net sale of 0 shares made by Zhao Hong , and a net sale of 0 shares made by Ascendent Silver (cayman) Limited .

In summary, during the past 3 months, insiders sold 0 shares of SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) were sold and 354,500 shares were bought by its insiders, resulting in a net purchase of 354,500 shares.

SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600)'s detailed insider trading history can be found in Insider Trading Tracker table.

SciClone Pharmaceuticals (Holdings) Ltd Insider Transactions

No Available Data

Ascendent Capital Partners II, L.P. Mailing Address

Above is the net worth, insider trading, and ownership report for Ascendent Capital Partners II, L.P.. Currently GuruFocus does not have mailing address information for Ascendent Capital Partners II, L.P..

Discussions on Ascendent Capital Partners II, L.P.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.